A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy

被引：0
|
作者：
Grierson, Patrick
Wang-Gillam, Andrea
Park, Haeseong
Pedersen, Katrina
Tan, Benjamin R.
Amin, Manik A.
Suresh, Rama
Trikalinos, Nikolaos
Liu, Jingxia
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Mayo Sch Grad Med Educ, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS793
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer which progressed on gemcitabine-based therapy
    Grierson, Patrick
    Suresh, Rama
    Tan, Benjamin R.
    Pedersen, Katrina Sophia
    Amin, Manik A.
    Park, Haeseong
    Trikalinos, Nikolaos
    Liu, Jingxia
    Lim, Kian-Huat
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer whose disease progressed on gemcitabine-based therapy
    Grierson, Patrick
    Suresh, Rama
    Tan, Benjamin R.
    Pedersen, Katrina Sophia
    Amin, Manik A.
    Park, Haeseong
    Trikalinos, Nikolaos
    Liu, Jingxia
    Lim, Kian-Huat
    Wang-gillam, Andrea
    Bansod, Sapana Prakashrao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A Pilot Study of Paricalcitol plus Nanoliposomal Irinotecan and 5-FU/LV in Advanced Pancreatic Cancer Patients after Progression on Gemcitabine-Based Therapy
    Grierson, Patrick M.
    Suresh, Rama
    Tan, Benjamin
    Pedersen, Katrina S.
    Amin, Manik
    Park, Haeseong
    Trikalinos, Nikolaos A.
    Liu, Jingxia
    Boice, Nicholas
    Brown, Amberly
    Bansod, Sapana
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    CLINICAL CANCER RESEARCH, 2023, 29 (23) : 4733 - 4739
  • [4] Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
    Yoo, C.
    Saborowski, A.
    Hyung, J.
    Wenzel, P.
    Kim, I.
    Wege, H.
    Kim, K-P
    Folprecht, G.
    Ryoo, B-Y
    Schuett, P.
    Cheon, J.
    Goetze, T. O.
    Ryu, H.
    Lee, J. S.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S235 - S235
  • [5] Multicenter retrospective analysis for efficacy and safety of liposomal irinotecan (nal-IRI) plus 5-FU/leucovorin (5-FU/LV) after progression on gemcitabine-based therapy in Korean patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC): A study by Korean Cancer Study Group (KCSG).
    Im, Hyeon-Su
    Kim, Kyu-Pyo
    Oh, Do-Youn
    Lee, Kyung-Hun
    Chon, Hong Jae
    Kim, Joo Hoon
    Kang, Myoung Joo
    Kim, Il-Hwan
    Lee, Guk Jin
    Oh, Sung Yong
    Choi, Younak
    Choi, Hye Jin
    Kim, Seung Tae
    Park, Joon Oh
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer
    Koji Kikuchi
    Akira Umemura
    Hiroyuki Nitta
    Hirokatsu Katagiri
    Masao Nishiya
    Noriyuki Uesugi
    Tamotsu Sugai
    Keisuke Imanari
    Akira Sasaki
    Surgical Case Reports, 8
  • [7] Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
    Ioka, T.
    Nakamori, S.
    Sugimori, K.
    Kanai, M.
    Ikeda, M.
    Ozaka, M.
    Furukawa, M.
    Okusaka, T.
    Kawabe, K.
    Furuse, J.
    Komatsu, Y.
    Sato, A.
    Shimizu, S.
    Chugh, P.
    Tang, R.
    Ueno, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] Gemcitabine(GEM) plus B-fluorouracil (5-FU) by modulated by leucovorin (LV) for advanced pancreatic cancer)
    Polyzos, A
    Tsavaris, N
    Kosmas, C
    Arnaoutis, T
    Apostolopoulos, P
    Vafiadis, I
    Tsatali, K
    Toskas, A
    Nikou, G
    ANNALS OF ONCOLOGY, 1998, 9 : 55 - 55
  • [9] Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study
    Chen, L-T.
    Macarulla Mercade, T.
    Lee, K-H.
    Lakatos, G.
    Wang-Gillam, A.
    Mirakhur, B.
    de Jong, F.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] 5-Fluorouracil/Leucovorin Combined with Irinotecan and Oxaliplatin (FOLFIRINOX) as Second-Line Chemotherapy in Patients with Advanced Pancreatic Cancer Who Have Progressed on Gemcitabine-Based Therapy
    Lee, Min Geun
    Lee, Sang Hyub
    Lee, Seung June
    Lee, Yoon Suk
    Hwang, Jin-Hyeok
    Ryu, Ji Kon
    Kim, Yong-Tae
    Kim, Dong Uk
    Woo, Sang Myung
    CHEMOTHERAPY, 2013, 59 (04) : 273 - 279
12345